A 47-year-old man with asymptomatic hepatitis C infection

JAMA

Volumn 275, Issue 13, 1996, Pages 1023-1029

  Sorrell, Michael F ^a   Walzer, Janet ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PENICILLIN DERIVATIVE; PYRIDOXINE;

ADJUVANT DISEASE; ADULT; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MALE; PRIORITY JOURNAL; SERODIAGNOSIS; SUBSTANCE ABUSE; SYPHILIS; THORAX RADIOGRAPHY; TUBERCULOSIS; VIRUS ISOLATION;

EID: 0029875683     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.13.1023     Document Type: Conference Paper

References (31)

1. Alter M. Epidemiology of hepatitis C in the West, Semin Liver Dis. 1995; 15:5-14.
2. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med. 1992;327:1906-1911.
3. Tong MJ, El-Farra NS, Reikes AE, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-1466.
4. Kiyosawa K, Sodeyama T, Tasaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma; analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671-675.
5. Alter MJ, Margolis HS, Krawezynskj K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med. 1992;327: 1899-1903.
6. Akahane Y, Kojima M, Sugai Y, et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med. 1994;120:748-752.
7. McCashland TM, Wright TL, Donovan JP, et al. Low incidence of intraspousal transmission of hepatitis C virus after liver transplantation. Liver Trans Surg. 1995;1:358-361.
8. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med. 1994;330:744-750.
9. Reinus JF, Enid L, Leikin L, et al. Failure to detect vertical transmission of hepatitis C virus. Ann Intern Med. 1992;117:881-886.
10. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA done derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;44:359-362.
11. Kleinman S, Alter H, Busch M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion. 1992;32:805-813.
12. De Medina M, Schiff ER. Hepatitis C: diagnostic assays. Semin Liver Dis. 1995;15:33-40.
13. Van Thiel DH, Caraceni P, Molloy PJ, et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy. J Hepatol. 1995;3:503-508.
14. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? Ann Intern Med. 1993;118:150-153.
15. Janes CH, Lindor KD. Outcome of patients admitted with complications after outpatient liver biopsies. Ann Intern Med. 1993;118:36-98.
16. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis. 1995; 15:82-91.
17. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 1995;32:1457-1462.
18. Janssen HLA, Brouwer JT, van der Mast R, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol. 1994;21:241-243.
19. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med. 1989;21:1501-1506.
20. Marcelline P, Boyer N, Giostra E, et al. Recombinant human-interferon inpatients with chronic non-T, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991;13:393-397.
21. DiBisceglie AM, Martin P, Kassianides C, et al. Recombinant Interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebocontrolled trial. N Engl J Med. 1989;321:1506-1510.
22. Martin P. Hepatitis C genotypes: the key to pathogenicity? Ann Intern Med. 1995;122:227-228.
23. Wright T, Terrault N. Interferon and hepatitis C. N Engl J Med. 1995; 332:1509-1511.
24. Marcellin P, Pouteau M, Martinot-Peignoux M, et al. Lack of benefit of escalating dosage of Interferon alfa in patients with chronic hepatitis C. Gastroenterology. 1995;109:156-165.
25. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus Interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 1994;107:812-817.
26. Van Thiel DH, Friedlander L, Fagiuoli S, et al. Response to interferon a therapy is influenced by the iron content of the liver. J Hepatol. 1994;20:410-415.
27. Lau JYN, Mizokami M, Ohno T, et al. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet. 1993;342:1208-1209.
28. Serfaty L, Chazouilleres O, Pawlotsky J-M, et al. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology. 1996;110:291-295.
29. Wright TL, Pereira B. Liver transplantation for chronic viral hepatitis. Liver Trans Surg. 1995;1:30-42.
30. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology. 1995;22:1863-1873.
31. Bennett WG, Inoue Y, Beck JK, et al. Justification of a single 6-month course of Interferon (IFN) for histologically mild chronic hepatitis C. Hepatology 1995;22(suppl to No. 4, pt 2):290A. Abstract.